Could a malaria drug boost leukemia treatment?
NCT ID NCT07022743
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial in Nigeria tests whether adding artesunate, a malaria drug, to the standard CML medication imatinib can improve treatment outcomes. 75 adults with chronic myeloid leukemia will receive either imatinib alone or imatinib plus artesunate. The goal is to see if the combination leads to better molecular remission and is safe for long-term use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imatinib and artesunate combination
What this could lead to
If it works, this could offer a more affordable and effective treatment option for CML patients, especially in low-income countries where second-line drugs are unavailable.
What could go wrong
This is a small Phase 2 trial with only 75 participants, so results may not apply to everyone. Artesunate's long-term safety for CML is not yet proven, and the combination may not work better than imatinib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife
Ile-Ife, Osun State, 3408, Nigeria